Search results for "marker"

showing 10 items of 3799 documents

Urinary excretion of heptanones, heptanoles and 2,5-heptanedione after controlled acute exposure of volunteers to n-heptane.

2018

A lack of well-established parameters and assessment values currently impairs biomonitoring of n-heptane exposure. Using controlled inhalation experiments, we collected information on urinary n-heptane metabolite concentrations and the time course of metabolite excretion. Relationships between external and internal exposure were analysed to investigate the suitability of selected metabolites to reflect n-heptane uptake. Twenty healthy, non-smoking males (aged 19-38 years, median 25.5) were exposed for 3 h to 167, 333 and 500 ppm n-heptane, each. Spot urine samples of the volunteers, collected before exposure and during the following 24 h, were analysed for heptane-2-one, 3-one, 4-one, 2,5-d…

AdultMaleMetaboliteUrinary systemUrine010501 environmental sciencesUrinalysisToxicology01 natural sciencesGas Chromatography-Mass SpectrometryHeptanesExcretionchemistry.chemical_compoundYoung AdultBiomonitoringHumansBiotransformation0105 earth and related environmental sciencesCreatinineHeptaneChromatographyInhalationEnvironmental Biomarkers010401 analytical chemistrySolid Phase ExtractionReproducibility of ResultsGeneral MedicineKetones0104 chemical sciencesRenal EliminationchemistryHeptanolEnvironmental MonitoringToxicology letters
researchProduct

Recurrence of pleomorphic adenoma of the parotid gland-predictive value of cadherin-11 and fascin

2008

The predictive value of cadherin-11, tenascin, fascin, and mucin-1 as markers for the likelihood of recurrence in pleomorphic adenoma of the parotid gland was examined. In this retrospective study we analysed 20 tumours from16 patients by immunohistochemistry. Staining intensities were measured using a semiquantitative scoring approach; localisation (tumour centre vs border) as well as clinical data were analysed and correlated with follow-up. Cadherin-11 was increased in recurrent tumours. However, no changes of fascin, tenascin or mucin-1 were observed. Cadherin-11 and fascin were increased in primary tumours of patients with later recurrence, with fascin upregulation restricted to the tu…

AdultMaleMicrobiology (medical)Pathologymedicine.medical_specialtyAdolescentAdenoma PleomorphicTenascinmacromolecular substancesPathology and Forensic MedicinePleomorphic adenomaDownregulation and upregulationBiomarkers TumormedicineHumansParotid GlandImmunology and AllergyRetrospective StudiesFascinbiologyCadherinMicrofilament ProteinsMucin-1MucinTenascinGeneral MedicineMiddle AgedCadherinsPrognosismedicine.diseaseImmunohistochemistryParotid NeoplasmsParotid glandmedicine.anatomical_structurebiology.proteinImmunohistochemistryFemaleNeoplasm Recurrence LocalCarrier ProteinsAPMIS
researchProduct

Influence of Female Sex Hormones on Ultra-Running Performance and Post-Race Recovery: Role of Testosterone

2021

In recent years, increasing numbers of women have participated in extremely long races. In adult males, there is a clear association between physiological levels of endogenous sex hormones and physical performance. However, the influence of plasmatic sex hormones and the effects of different types of hormonal contraception (HC) on the modulation of physical performance in adult females remain to be fully clarified. Eighteen female ultra-endurance athletes were recruited to participate in the study. Different variables were studied, including hematological parameters, body mass index, and body composition. Strength measurements were obtained using the squat-jump and hand-grip test. A repeate…

AdultMaleMultivariate analysismedicine.drug_classHealth Toxicology and Mutagenesismedia_common.quotation_subjectPhysiologyfemale athletesArticleRunningmuscle damageMedicineHumansTestosteroneMenstrual cyclemedia_commonultra-enduranceMuscle fatiguehormonesbusiness.industryhormonal contraceptionRPublic Health Environmental and Occupational HealthTestosterone (patch)physical performanceHormonal contraceptionEstrogenAthletesPhysical EnduranceMedicineFemalemuscle fatiguebusinessBody mass indexBiomarkersHormone
researchProduct

Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection.

2009

Summary.  B-lymphocyte stimulator/B activating factor (BLyS/BAFF) is a tumour necrosis factor-family cytokine that plays a key role in generating and maintaining the mature B-cell pool. BLyS/BAFF expression by macrophages is stimulated by interferon-γ and interleukin-10, and its serum levels are increased in chronic hepatitis C (CHC). The aim of this study was to assess serum levels of BLyS/BAFF in patients with acute hepatitis C (AHC) and correlate them with disease outcome. We studied 28 patients with AHC (14 males, mean age 59.3 ± 15 years), followed for at least 7 months since onset, comparing them with 86 CHC patients and 25 healthy blood donors (HBD). BLyS/BAFF levels were assessed at…

AdultMaleNecrosismedicine.medical_treatmentAcute hepatitis CVirusYoung AdultVirologyB-Cell Activating FactorMedicineHumansIn patientB-cell activating factorAgedAged 80 and overHepatologybusiness.industryHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CChronic infectionInfectious DiseasesCytokineImmunologyFemaleAcute hepatitis Cmedicine.symptombusinessBiomarkersJournal of viral hepatitis
researchProduct

Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients

2008

Background: Promyelocytic leukemia (PML) tumor suppressor gene plays a key role in acute PML pathogenesis but its involvement in pathogenesis and prognosis of solid cancers has not been defined yet. Patients and methods: In all, 62 ampullary adenocarcinoma patients who underwent curative surgery between 1996 and 2005 were included. Expression analysis of PML was carried out by immunohistochemical staining and correlated with disease-free survival (DFS) and overall survival (OS). Results: In 24 tumor specimens (38.7%), PML was classified as absent, in 16 (25.8%) as focally expressed and in 22 (35.5%) as diffusely expressed. By univariate analysis, DFS was significantly influenced by patholog…

AdultMaleOncologyAmpulla of Vatermedicine.medical_specialtyPathology(PML)ampullary cancerTumor suppressor geneCommon Bile Duct NeoplasmsAdenocarcinomaPromyelocytic Leukemia ProteinsurvivalCohort StudiesPathogenesispromyelocytic leukemia gene expressionPromyelocytic leukemia proteinampulla of vater cancer; promyelocytic leukemia gene expression; prognosisInternal medicineBiomarkers TumorHumansMedicinePathologicalAgedRetrospective StudiesAged 80 and overUnivariate analysisPMLbiologybusiness.industryTumor Suppressor ProteinsNuclear Proteinsampullary cancerHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisGene Expression Regulation NeoplasticLeukemiaOncologyPML; ampullary cancer; survivalbiology.proteinImmunohistochemistryT-stageampulla of vater cancerFemalebusinessTranscription FactorsAnnals of Oncology
researchProduct

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004

Abstract Purpose: No chemotherapy regimen, including the widely used combination of gemcitabine/cisplatin, confers significantly improved survival over any other in metastatic non-small cell lung cancer (NSCLC); however, the selection of patients according to key genetic characteristics can help to tailor chemotherapy. Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. Experimental Design: Patients were part of a large randomized trial carried out from September 1998 to July 2000, comparing gemcitabine/cisplatin versus gemcit…

AdultMaleOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsDNA RepairRibonucleoside Diphosphate Reductasemedicine.medical_treatmentAntineoplastic AgentsBiologyVinorelbineDeoxycytidineCarcinoma Non-Small-Cell LungInternal medicineRibonucleotide ReductasesmedicineHumansRNA MessengerLung cancerAgedCisplatinChemotherapyPredictive markerTumor Suppressor ProteinsDNAMiddle AgedEndonucleasesPrognosismedicine.diseaseGemcitabineChemotherapy regimenGemcitabineDNA-Binding ProteinsTreatment OutcomeOncologyFemaleCisplatinERCC1medicine.drugClinical Cancer Research
researchProduct

Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers

2019

Background The identification of appropriate biomarkers is essential to support important clinical decisions in patients with prostate cancer. The aim of our study was a systematic bioinformatical analysis of the mRNA expression of all genes available for the prostate adenocarcinoma cohort of The Cancer Genome Atlas (TCGA), regarding their potential prognostic and diagnostic role. Methods The study cohort comprises 499 patients (TCGA prostate cancer cohort). mRNA expression data were available for approx. 20,000 genes. The bioinformatical statistical pipeline addressed gene expression differences in tumor vs. benign prostate tissue (including gene set enrichment analysis, GSEA) in samples f…

AdultMaleOncologyBiochemical recurrencemedicine.medical_specialtyBiomedical ResearchMultivariate analysisBioinformaticsUrology030232 urology & nephrologyAdenocarcinomalcsh:RC870-923PrognosticCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineBiomarkers TumormedicineHumansDiagnosticEpigeneticsAgedProstate cancerProportional hazards modelbusiness.industryHazard ratiomRNA expressionProstatic NeoplasmsGeneral MedicineMiddle Agedlcsh:Diseases of the genitourinary system. UrologyPrognosismedicine.diseaseGene Expression Regulation NeoplasticReproductive Medicine030220 oncology & carcinogenesisCohortBiomarker (medicine)businessBiomarkersResearch ArticleBMC Urology
researchProduct

The clinical value of tumor burden at diagnosis in Hodgkin lymphoma

2004

BACKGROUND The authors investigated the clinical role of tumor burden (TB) in patients with Hodgkin lymphoma, relating this parameter to most of the current clinical and prognostic factors and to the best predictive multifactorial models. METHODS The volume of TB at diagnosis was measured directly from the initial staging computed tomography scans in 351 patients who were treated on standard protocols. The mean patient age was 34.0 years ± 16.4 years. Forty-six patients had clinical Stage I disease, 201 patients had Stage II disease, 64 patients had Stage III disease, and 40 patients had Stage IV disease. There were 146 symptomatic patients. Overall survival (OS), disease-free survival (DFS…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsMultivariate analysisAdolescentBody Surface AreaDiseaseLogistic regressionText miningPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansTreatment FailureStage (cooking)Neoplasm StagingRetrospective StudiesBody surface areabusiness.industryRemission InductionCancerMiddle AgedPrognosismedicine.diseaseHodgkin DiseaseSurgeryLymphomaSurvival RateOncologyFemaleTomography X-Ray ComputedbusinessCancer
researchProduct

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma : results From the Open-Label, Multicenter, Phase II DAWN Study

2018

Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee–assessed overall response rate (ORR; complete response plus partial response). Exploratory analyses of T-cell subsets in peripheral blood (baseline/cycle …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classFollicular lymphomaPhases of clinical researchTyrosine-kinase inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePiperidinesRecurrenceT-Lymphocyte SubsetsChemoimmunotherapyInternal medicineBiomarkers TumormedicineHumansLymphoma FollicularProtein Kinase InhibitorsAgedAged 80 and overManchester Cancer Research Centrebusiness.industryResearchInstitutes_Networks_Beacons/mcrcAdenineMiddle Agedmedicine.diseaseLymphomaPyrimidinesTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisIbrutinibPyrazolesFemaleRefractory Follicular LymphomabusinessProgressive disease030215 immunology
researchProduct

Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity

2006

This study tested the hypothesis that GLUT-1 is a marker of radioresistance in oral squamous cell carcinomas (OSCC). A GLUT-1 labeling index (LI) was determined by immunohistochemistry in 40 pretreatment OSCC biopsies. Radiation responses were categorized by histopathology of the resection specimens. Associations between the LI and radiation response, Kaplan-Meier survival estimates and Cox regression analysis for the variables GLUT-1, T-stage, N-stage and chemotherapy were examined. The median LI was 64.2% (range 14-100%). Tumors with65% of GLUT-1+cells were more resistant to radiation (p=0.023). Overall survival was higher (p=0.044) for subjects with low LI (median value) than those with …

AdultMaleOncologyendocrine systemCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentAntineoplastic AgentsRadiation ToleranceImmunoenzyme TechniquesRadioresistanceInternal medicineBiomarkers TumorHumansMedicineAgedRetrospective StudiesGlucose Transporter Type 1Chemotherapybusiness.industryProportional hazards modelHead and neck cancerMiddle AgedPrognosismedicine.diseaseCombined Modality TherapySurvival AnalysisNeoplasm ProteinsRadiation therapystomatognathic diseasesTreatment OutcomeOncologyEpidermoid carcinomaCarcinoma Squamous CellImmunohistochemistryFemaleMouth NeoplasmsHistopathologyOral Surgerybusinesshormones hormone substitutes and hormone antagonistsOral Oncology
researchProduct